- Home
- STBA vs NVAX Comparison
STBA vs NVAX Comparison
Compare STBA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STBA
- NVAX
- Stock Information
- Founded
- STBA 1902
- NVAX 1987
- Country
- STBA United States
- NVAX United States
- Employees
- STBA N/A
- NVAX N/A
- Industry
- STBA Major Banks
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STBA Finance
- NVAX Health Care
- Exchange
- STBA Nasdaq
- NVAX Nasdaq
- Market Cap
- STBA 1.5B
- NVAX 1.3B
- IPO Year
- STBA N/A
- NVAX 1995
- Fundamental
- Price
- STBA $38.02
- NVAX $8.56
- Analyst Decision
- STBA Hold
- NVAX Buy
- Analyst Count
- STBA 3
- NVAX 7
- Target Price
- STBA $42.00
- NVAX $14.29
- AVG Volume (30 Days)
- STBA 111.4K
- NVAX 6.8M
- Earning Date
- STBA 10-16-2025
- NVAX 11-11-2025
- Dividend Yield
- STBA 3.53%
- NVAX N/A
- EPS Growth
- STBA N/A
- NVAX N/A
- EPS
- STBA 3.40
- NVAX 2.54
- Revenue
- STBA $388,489,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- STBA $7.12
- NVAX $61.69
- Revenue Next Year
- STBA $5.09
- NVAX N/A
- P/E Ratio
- STBA $11.34
- NVAX $3.37
- Revenue Growth
- STBA 1.05
- NVAX 9.22
- 52 Week Low
- STBA $30.84
- NVAX $5.01
- 52 Week High
- STBA $45.46
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- STBA 43.99
- NVAX 59.53
- Support Level
- STBA $38.52
- NVAX $7.83
- Resistance Level
- STBA $39.60
- NVAX $8.31
- Average True Range (ATR)
- STBA 0.76
- NVAX 0.37
- MACD
- STBA -0.16
- NVAX 0.04
- Stochastic Oscillator
- STBA 12.98
- NVAX 92.36
About STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.